Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20

Company Overview - Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [4] - The company's vaccines are designed to be administered in pill form, which can be stored and shipped without refrigeration, thus eliminating the risk of needle-stick injury [4] - Vaxart's current development programs include vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [4] Upcoming Events - Vaxart will provide a business update and report financial results for the full year ended December 31, 2024, after market close on March 20, 2025 [2] - A conference call hosted by the senior management team will take place on the same day at 4:30 p.m. ET, with access details provided for investors [2][3] - Investors are encouraged to submit written questions in advance of the conference call [2]